HR Execs on the Move


 
Absci is the AI-powered synthetic biology company unlocking the potential of proteins as the next generation of therapeutics. We built our Integrated Drug Creation™ Platform to accelerate discovery of novel biotherapeutic drug candidates and generation of the cell lines to manufacture them in a single efficient process. Biotech and pharma innovators partner with us to develop new protein-based drugs, including those that may be impossible to make with other technologies. Our goal is to enable the creation of better medicines by Translating Ideas into Drugs.
  • Number of Employees: 100-250
  • Annual Revenue: $10-50 Million
  • www.absci.com
  • 18105 SouthEast Mill Plain Boulevard
    Vancouver, WA USA 98683
  • Phone: 360.949.1041

Executives

Name Title Contact Details
Zach Jonasson
Chief Financial Officer and Chief Business Officer Profile
Jack Gold
Chief Marketing Officer Profile
Denise Dettore
Chief People Officer Profile
Todd Bedrick
SVP Chief Accounting Officer Profile

Similar Companies

MDxHealth

MDxHealth is a multinational healthcare company that provides actionable molecular diagnostic information to personalize the diagnosis and treatment of cancer.

Aker BioMarine

Aker BioMarine is a Norwegian fishing and biotech company providing krill products through a fully documented and secured catch and process chain.

great healthworks

great healthworks is a Fort Lauderdale, FL-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Perimeter Resources

Perimeter Resources is a Houston, TX-based company in the Healthcare, Pharmaceuticals, & Biotech sector.

T-knife

T-knife Therapeutics is a biopharmaceutical company dedicated to developing novel therapeutics to fight cancer, initially focused on T cell receptor (TCR) engineered T cell therapies (TCR-Ts), a modality that holds the potential to generate transformative responses in patients with solid tumors. The Company`s unique approach leverages its proprietary HuTCR mouse platform, a next-generation T cell receptor and epitope discovery engine that produces fully human, tumor-specific TCRs, naturally selected in vivo for optimal affinity and high specificity. T-knife is advancing a portfolio of TCR-T product candidates against targets with high unmet medical need, including cancer testis antigens, oncoviral antigens and commonly shared tumor-driving neoantigens. T-knife was founded by leading T-cell and immunology experts using technology developed at the Max Delbruck Center for Molecular Medicine together with Charité – Universitätsmedizin Berlin.